4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
12.57
+0.43 (3.54%)
Oct 19, 2026, 10:08 AM EDT - Market open
4D Molecular Therapeutics Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, 4D Molecular Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $28.09. The average 1-year stock price forecast is 123.47% higher than the current stock price, while the lowest is $18 (+43.20%) and the highest is $37 (+194.35%).
Price Target: $28.09 (+123.47%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for 4D Molecular Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 9 | 9 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 12 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Maintains $28 | Buy | Maintains | $28 | +122.75% | Oct 13, 2026 |
| Chardan Capital | Chardan Capital | Buy Maintains $25 | Buy | Maintains | $25 | +98.89% | Oct 7, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Sep 29, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $29 → $33 | Buy | Reiterates | $29 → $33 | +162.53% | Sep 29, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Upgrades n/a | Buy | Upgrades | n/a | n/a | Sep 21, 2026 |
Financial Forecast
Revenue This Year
13.26M
from 85.21M
Decreased by -84.44%
Revenue Next Year
20.63M
from 13.26M
Increased by 55.65%
EPS This Year
-4.15
from -2.42
EPS Next Year
-4.09
from -4.15
EPS and Forward PE are based on non-GAAP adjusted numbers.